NASDAQ:CRDF Cardiff Oncology Q2 2024 Earnings Report $2.90 -0.04 (-1.36%) As of 04/24/2025 04:00 PM Eastern Earnings HistoryForecast Cardiff Oncology EPS ResultsActual EPS-$0.26Consensus EPS -$0.25Beat/MissMissed by -$0.01One Year Ago EPS-$0.25Cardiff Oncology Revenue ResultsActual Revenue$0.16 millionExpected Revenue$0.12 millionBeat/MissBeat by +$40.00 thousandYoY Revenue GrowthN/ACardiff Oncology Announcement DetailsQuarterQ2 2024Date8/8/2024TimeAfter Market ClosesConference Call DateThursday, August 8, 2024Conference Call Time4:30PM ETUpcoming EarningsCardiff Oncology's Q1 2025 earnings is scheduled for Thursday, May 1, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Cardiff Oncology Q2 2024 Earnings Call TranscriptProvided by QuartrAugust 8, 2024 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:01Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer Please be advised that today's conference is being recorded. I would now like to turn the conference call over to Kiki Patel of Gail Martin Group. Please go ahead. Speaker 100:00:41Thank you, operator. Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander and Chief Financial Officer, Jamie Levine. During this conference call, management will make forward looking statements, including without limitation, statements related to guidance, results and the timing of data readouts for our Vansertib clinical trials. These forward looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties. Speaker 100:01:20Factors that could cause results to be different from these statements include factors the company describes in the section titled Risk Factors in its annual report on Form 10 ks filed with the SEC for the year ended December 31, 2023. Cardiff Oncology undertakes no duty or obligation to update any forward looking statements as a result of new information, future events or changes in its expectations. With that, I turn the call over to Chief Executive Officer, Mark Erlander. Mark? Speaker 200:01:50Thank you, Kiki, and good afternoon, everyone, and thank you for joining our business update conference call for the Q2 of 2024. These are certainly energizing times at Cardiff Oncology as we activate sites, enroll patients in our CARTIP-four trial in RAS mutated metastatic colorectal cancer or MCRC. The interactions we're having with the physicians and other professionals at the trial site reinforce our own excitement as the potential to bring a more effective therapy to this large patient population of nearly 50,000 new patients a year in the U. S. Alone. Speaker 200:02:29Specifically, the totality of the data from our Phase 1v2 and Ensembl second line mCRC trials demonstrates onvancertib has the potential to shift the treatment paradigm for all RAS mutated mCRC, not just subgroups of KRAS. We say this because first, there have been no new therapies approved for these patients over the past 20 years. 2nd, there are no competing clinical trials for this patient population. And 3rd, unlike prior PLK1 inhibitors, ombansertib is well tolerated when combined with chemotherapy, which also opens the door to other chemo combinations for additional cancer indications. So let's dive in. Speaker 200:03:16On today's call, we will cover 4 topics. First, I will discuss our lead program in MTRC and provide updates around our ongoing CARTWR trial. 2nd, I will provide an update on our pancreatic cancer program. 3rd, I will provide a brief overview of our continued encouraging preclinical data demonstrating on Vansertib's activity in other cancer indications with unmet clinical need beyond RAS mutated mCRC. And finally, we will talk about our financial position that we disclosed today in our Form 10 Q. Speaker 200:03:57So let's begin. This quarter, we have been intensely focused on the clinical execution of our CARDIP-four trial evaluating the contribution of onvansertib in first line RAS mutated mCRC. As a reminder, CARTF004 is our ongoing Phase 2 trial evaluating onvansertib in combination with current standard of care, which consists of either FOLFIRI plus bev or FOLFOX plus bev. The trial is currently active in 33 sites and we plan to enroll 90 patients who will be randomized to receive either a 20 milligram or a 30 milligram dose of odevansertib plus standard of care or standard of care alone. Our team at Cardiff Oncology alongside our clinical execution partner Pfizer Ignite is diligently working on the enrollment of the trial. Speaker 200:04:53We continue to leverage Pfizer's resources and capabilities in multiple areas to drive enrollment. We also appreciate the commitment and the clinical efforts of our enthusiastic investigators who have been judiciously screening patients across our active sites. Based on the current pace of enrollment over the past few months, we continue to plan on releasing an initial data readout later this year as we previously guided. We expect this will include objective response rate data for approximately half of the patients we plan to enroll in the trial. Now I'd like to turn to our 2nd agenda item, an update on our pancreatic cancer program focused on metastatic pancreatic ductal adenocarcinoma or PDAC. Speaker 200:05:43In September of last year, we released data from our Phase 2 trial for metastatic PDAC in the 2nd line setting. In this single arm trial, patients received onvansertib in combination with the chemotherapy regimen of liposomal, irinotecan, leucoborin and 5FU. After discussing the results with our investigators, we decided the next step of our PDAC program would be an investigator initiated trial in the first line setting combining ombansertib with standard of care, gemAbraxane. Today, we are sharing an update to our plans in metastatic PDAC because earlier this year, Nalili Fox was approved for first line metastatic PDAC after the NAPOLE three trial showed significantly greater improvement in overall survival and progression 3 survival with first line malairefos compared to gemabraxane. As a result of this change to the first line standard of care, we have decided to support a first line investigator initiated PDAC trial that combines onvanceertib with Nelire FOX. Speaker 200:06:53And recall that 3 of the 4 drugs that comprised the Nelire FOX first line regimen were the same drug combined with ombansertib in our prior second line PDAC trial. This new trial will replace the first line PDAC investigator initiated trial combining omsertib with gemabrasing, which was still in an early stage and had not started to enroll patients. We will provide further updates on the onvansertib, now ERIFOX, investigator initiated trial in the coming months. Now I'd like to transition to the 3rd item on our agenda, which is our continued success in identifying other cancer indications where ovansertib may be clinically efficacious. Previously, in preclinical studies, ovansertib has been shown to have activity in BRAF's wild type mCRC, ER positive breast cancer, triple negative breast cancer and platinum resistant ovarian cancer. Speaker 200:07:56Last month, we published preclinical data on a new indication within ovarian cancer in the peer reviewed journal Cell Death and Disease, which is a portfolio member of the journal Nature. Specifically, the data evaluated on Bancertib and ovarian cancers that are resistant to PARP inhibitors. In the published study, the combination of onvansertib and olaparib, a PARP inhibitor approved in ovarian cancer was tested both in vitro and in vivo and BRCA1 mutated and wild type ovarian cancer models. In vitro, the combination of onvancertib and olaparib was synergistic in ovarian cancer cell lines and demonstrate inhibition of tumor growth. In vivo, the combination was well tolerated, slowed tumor progression and prolonged survival in patient derived xenograft models resistant to olaparib. Speaker 200:08:50Resistance to olaparib has been observed in clinical settings and has been a challenge to overcome. Moreover, these findings underscore the ability of ONVATTRIB to overcome resistance to PARP inhibitors in high grade serous ovarian carcinomas, which could make a significant impact in the treatment landscape for ovarian cancer. Overall, we are still determining our path forward in ovarian cancer. However, we are highly encouraged by the totality of the data generated from our recent publication and AACR poster that demonstrates ONVASTRU's ability to effectively re sensitize ovarian cancer to treatment. Now, I would like to turn the call over to Jamie to discuss our final agenda item, our Q2 2024 financial update. Speaker 300:09:42Thank you, Mark. Earlier today, we issued a press release and filed a Form 10 Q with the SEC, which contain our financial results for the Q2 ending June 30, 2024. Turning to our balance sheet, cash and short term investments as of June 30, 2024 totaled $60,300,000 and our cash used in operating activities was $9,200,000 in Q2 2024. Today, we're also updating our cash runway guidance based on our most up to date cash forecast. As a result, we believe that our current cash resources provide us with runway through the end of the Q3 of 2025, whereas previously we had expected runway into the Q3 of 2025. Speaker 300:10:32With that, I'll turn the call back over to Mark. Speaker 200:10:36Thank you, Jamie. I would now like to close the call by emphasizing our confidence in our clinical development strategy for our lead program in RAS mutated MCRC and enthusiasm for our upcoming data readout of CARDIP-four later this year. Collectively, the data we have released throughout the past year from our Phase 1btwo study, ENSEMBLE trial and at AACR gives us conviction that adding onvanceertib to standard of care has the potential to change the treatment paradigm for the entire first line, RAS mutated, mCRC patient population. And we believe that such an outcome would create enormous value for our stakeholders and positively impact the large population of patients living with RAS mutated mCRC. With that, I will now open the call up for questions. Speaker 200:11:34Operator? Operator00:11:37Thank you. We'll now begin the question and answer session. And your first question comes from the line of Mark Frahm of TD Cowen. Please go ahead. Speaker 400:12:14Thanks for taking my questions. Maybe first off, last quarter, you noted that kind of enrollment trends in the 4 trial had maybe been a bit slower than you'd anticipate when you open the trial. Speaker 300:12:26Just Speaker 400:12:27curious, has that kind of held steady? Has that enrollment held steady over the summer? Or have you seen some acceleration in that enrollment trend? Speaker 200:12:37Thanks, Mark. Enrollment is tracking quite well and is tracking with our guidance of having an initial look at the data later this year. And part of the reason why it's doing well is because we have Pfizer Ignite as a strong partner and we've been able to leverage a lot of their capabilities and being able to drive the enrollment. I think the other things that really do help that I mentioned earlier on the call is that there are no new drugs for 20 years for these RAS mutated patients in first line in CRC. And also importantly, there are no competing trials. Speaker 200:13:19So to answer your question, yes, we're on track with the guidance of initial look later this year. Speaker 400:13:26Okay. Thanks. That's very helpful. And then maybe on the pancreatic trial that you are going to start up. I think nalfurion access are obviously been approved, but at least in our conversations with physicians, it's not 100% clear that it's going to get broadly adopted as a true kind of broad standard of care. Speaker 400:13:49So I guess, why be kind of aggressive on adopting that now kind of for this initial proof of concept for in pancreatic versus maybe using some of the older regimens that are also potentially a bit better tolerated than that regimen? Speaker 200:14:06Yes. Really two answers to that question. I mean the first is that the now ARIFOX really 3 of the 4 chemo agents, we've already combined with onvanceertib in second line and have good data from that. And so we believe that along with our preclinical work in this area. So that's really the first part of the answer to the question. Speaker 200:14:30The second is really that we are showing really good tolerability of ombansertib or tip in combination with these chemo agents and really the only chemo that we haven't combined it with is the oxaliplatin which is part of the null irrefoxed. But really oxaliplatin really does not have any overlapping toxicities with onvanceertib. So we do feel confident that we can come in with this more aggressive chemo and combining and adding value to that because we believe that this is really the type of regimen that is showing the superiority and efficacy in first line. Speaker 400:15:14Okay. Thank you. Operator00:15:19Your next question comes from the line of Andy Scheife of William Blair. Please go ahead. Speaker 400:15:27Great. Thanks for taking our questions. Maybe Speaker 500:15:31kind of extend from Mark's question earlier in the call. Just curious about whether you could comment on the level of excitement and kind of scientific validation with the change of the IST in pancreatic cancer. Obviously, I think it's well validated that onvansertib synergy with irinotecan, which is now included in the regimen versus the gimabraxane regimen before. I'm curious about your view on that. And then in terms of the potential ovarian cancer entry, there's obviously new therapy, new cancer in the form of ADCs. Speaker 500:16:19So you've looked at chemotherapy, you've looked at targeted therapy, combinations, PARP. So just curious about whether you've done or plan do any sort of combinatorial work in the ADC field as well? Thanks. Speaker 200:16:35Thanks Andy for both of those questions. I'd say to answer your first question, really the irinotecan synergy is one of the main reasons we are going with the combination with Naleri Fox in first line. Also the PI that is that we're working with for this new investigator initiated trial has already has experience in our second line pancreatic trial and really was the a huge proponent enthusiastic in going into first line. So that was really he knows our drug, he knows it's well tolerated and he's very excited about going into first line. To answer your other question about ovarian cancer and ADC combination, we are currently pre clinically looking at ADCs in combination with onvansertib, not only ovarian, not specific only on ovarian, but we are really exploring that in several other areas that where ADCs have been approved. Speaker 500:17:41That's helpful. Thank you so much. Speaker 200:17:42Sure. Thanks, Andy. Operator00:18:04There are no more questions. I will now turn the conference back over to Mark Erlander for closing remarks. Speaker 200:18:11Thank you, operator, and this concludes our conference call. Thank you again everybody for joining us this afternoon. Good day. Operator00:18:20Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallCardiff Oncology Q2 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cardiff Oncology Earnings HeadlinesCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve PatientsApril 23 at 4:15 PM | globenewswire.comCardiff Oncology completes patient enrollment in CRDF-004 trialApril 16, 2025 | markets.businessinsider.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 25, 2025 | Paradigm Press (Ad)Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 15, 2025 | globenewswire.comCardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal CancerApril 15, 2025 | globenewswire.comCardiff Oncology (CRDF) Receives a Buy from Piper SandlerApril 14, 2025 | markets.businessinsider.comSee More Cardiff Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email. Email Address About Cardiff OncologyCardiff Oncology (NASDAQ:CRDF), a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.View Cardiff Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step InWhy It May Be Time to Buy CrowdStrike Stock Heading Into EarningsCan IBM’s Q1 Earnings Spark a Breakout for the Stock? Upcoming Earnings AbbVie (4/25/2025)AON (4/25/2025)Colgate-Palmolive (4/25/2025)HCA Healthcare (4/25/2025)NatWest Group (4/25/2025)Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:01Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer Please be advised that today's conference is being recorded. I would now like to turn the conference call over to Kiki Patel of Gail Martin Group. Please go ahead. Speaker 100:00:41Thank you, operator. Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander and Chief Financial Officer, Jamie Levine. During this conference call, management will make forward looking statements, including without limitation, statements related to guidance, results and the timing of data readouts for our Vansertib clinical trials. These forward looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties. Speaker 100:01:20Factors that could cause results to be different from these statements include factors the company describes in the section titled Risk Factors in its annual report on Form 10 ks filed with the SEC for the year ended December 31, 2023. Cardiff Oncology undertakes no duty or obligation to update any forward looking statements as a result of new information, future events or changes in its expectations. With that, I turn the call over to Chief Executive Officer, Mark Erlander. Mark? Speaker 200:01:50Thank you, Kiki, and good afternoon, everyone, and thank you for joining our business update conference call for the Q2 of 2024. These are certainly energizing times at Cardiff Oncology as we activate sites, enroll patients in our CARTIP-four trial in RAS mutated metastatic colorectal cancer or MCRC. The interactions we're having with the physicians and other professionals at the trial site reinforce our own excitement as the potential to bring a more effective therapy to this large patient population of nearly 50,000 new patients a year in the U. S. Alone. Speaker 200:02:29Specifically, the totality of the data from our Phase 1v2 and Ensembl second line mCRC trials demonstrates onvancertib has the potential to shift the treatment paradigm for all RAS mutated mCRC, not just subgroups of KRAS. We say this because first, there have been no new therapies approved for these patients over the past 20 years. 2nd, there are no competing clinical trials for this patient population. And 3rd, unlike prior PLK1 inhibitors, ombansertib is well tolerated when combined with chemotherapy, which also opens the door to other chemo combinations for additional cancer indications. So let's dive in. Speaker 200:03:16On today's call, we will cover 4 topics. First, I will discuss our lead program in MTRC and provide updates around our ongoing CARTWR trial. 2nd, I will provide an update on our pancreatic cancer program. 3rd, I will provide a brief overview of our continued encouraging preclinical data demonstrating on Vansertib's activity in other cancer indications with unmet clinical need beyond RAS mutated mCRC. And finally, we will talk about our financial position that we disclosed today in our Form 10 Q. Speaker 200:03:57So let's begin. This quarter, we have been intensely focused on the clinical execution of our CARDIP-four trial evaluating the contribution of onvansertib in first line RAS mutated mCRC. As a reminder, CARTF004 is our ongoing Phase 2 trial evaluating onvansertib in combination with current standard of care, which consists of either FOLFIRI plus bev or FOLFOX plus bev. The trial is currently active in 33 sites and we plan to enroll 90 patients who will be randomized to receive either a 20 milligram or a 30 milligram dose of odevansertib plus standard of care or standard of care alone. Our team at Cardiff Oncology alongside our clinical execution partner Pfizer Ignite is diligently working on the enrollment of the trial. Speaker 200:04:53We continue to leverage Pfizer's resources and capabilities in multiple areas to drive enrollment. We also appreciate the commitment and the clinical efforts of our enthusiastic investigators who have been judiciously screening patients across our active sites. Based on the current pace of enrollment over the past few months, we continue to plan on releasing an initial data readout later this year as we previously guided. We expect this will include objective response rate data for approximately half of the patients we plan to enroll in the trial. Now I'd like to turn to our 2nd agenda item, an update on our pancreatic cancer program focused on metastatic pancreatic ductal adenocarcinoma or PDAC. Speaker 200:05:43In September of last year, we released data from our Phase 2 trial for metastatic PDAC in the 2nd line setting. In this single arm trial, patients received onvansertib in combination with the chemotherapy regimen of liposomal, irinotecan, leucoborin and 5FU. After discussing the results with our investigators, we decided the next step of our PDAC program would be an investigator initiated trial in the first line setting combining ombansertib with standard of care, gemAbraxane. Today, we are sharing an update to our plans in metastatic PDAC because earlier this year, Nalili Fox was approved for first line metastatic PDAC after the NAPOLE three trial showed significantly greater improvement in overall survival and progression 3 survival with first line malairefos compared to gemabraxane. As a result of this change to the first line standard of care, we have decided to support a first line investigator initiated PDAC trial that combines onvanceertib with Nelire FOX. Speaker 200:06:53And recall that 3 of the 4 drugs that comprised the Nelire FOX first line regimen were the same drug combined with ombansertib in our prior second line PDAC trial. This new trial will replace the first line PDAC investigator initiated trial combining omsertib with gemabrasing, which was still in an early stage and had not started to enroll patients. We will provide further updates on the onvansertib, now ERIFOX, investigator initiated trial in the coming months. Now I'd like to transition to the 3rd item on our agenda, which is our continued success in identifying other cancer indications where ovansertib may be clinically efficacious. Previously, in preclinical studies, ovansertib has been shown to have activity in BRAF's wild type mCRC, ER positive breast cancer, triple negative breast cancer and platinum resistant ovarian cancer. Speaker 200:07:56Last month, we published preclinical data on a new indication within ovarian cancer in the peer reviewed journal Cell Death and Disease, which is a portfolio member of the journal Nature. Specifically, the data evaluated on Bancertib and ovarian cancers that are resistant to PARP inhibitors. In the published study, the combination of onvansertib and olaparib, a PARP inhibitor approved in ovarian cancer was tested both in vitro and in vivo and BRCA1 mutated and wild type ovarian cancer models. In vitro, the combination of onvancertib and olaparib was synergistic in ovarian cancer cell lines and demonstrate inhibition of tumor growth. In vivo, the combination was well tolerated, slowed tumor progression and prolonged survival in patient derived xenograft models resistant to olaparib. Speaker 200:08:50Resistance to olaparib has been observed in clinical settings and has been a challenge to overcome. Moreover, these findings underscore the ability of ONVATTRIB to overcome resistance to PARP inhibitors in high grade serous ovarian carcinomas, which could make a significant impact in the treatment landscape for ovarian cancer. Overall, we are still determining our path forward in ovarian cancer. However, we are highly encouraged by the totality of the data generated from our recent publication and AACR poster that demonstrates ONVASTRU's ability to effectively re sensitize ovarian cancer to treatment. Now, I would like to turn the call over to Jamie to discuss our final agenda item, our Q2 2024 financial update. Speaker 300:09:42Thank you, Mark. Earlier today, we issued a press release and filed a Form 10 Q with the SEC, which contain our financial results for the Q2 ending June 30, 2024. Turning to our balance sheet, cash and short term investments as of June 30, 2024 totaled $60,300,000 and our cash used in operating activities was $9,200,000 in Q2 2024. Today, we're also updating our cash runway guidance based on our most up to date cash forecast. As a result, we believe that our current cash resources provide us with runway through the end of the Q3 of 2025, whereas previously we had expected runway into the Q3 of 2025. Speaker 300:10:32With that, I'll turn the call back over to Mark. Speaker 200:10:36Thank you, Jamie. I would now like to close the call by emphasizing our confidence in our clinical development strategy for our lead program in RAS mutated MCRC and enthusiasm for our upcoming data readout of CARDIP-four later this year. Collectively, the data we have released throughout the past year from our Phase 1btwo study, ENSEMBLE trial and at AACR gives us conviction that adding onvanceertib to standard of care has the potential to change the treatment paradigm for the entire first line, RAS mutated, mCRC patient population. And we believe that such an outcome would create enormous value for our stakeholders and positively impact the large population of patients living with RAS mutated mCRC. With that, I will now open the call up for questions. Speaker 200:11:34Operator? Operator00:11:37Thank you. We'll now begin the question and answer session. And your first question comes from the line of Mark Frahm of TD Cowen. Please go ahead. Speaker 400:12:14Thanks for taking my questions. Maybe first off, last quarter, you noted that kind of enrollment trends in the 4 trial had maybe been a bit slower than you'd anticipate when you open the trial. Speaker 300:12:26Just Speaker 400:12:27curious, has that kind of held steady? Has that enrollment held steady over the summer? Or have you seen some acceleration in that enrollment trend? Speaker 200:12:37Thanks, Mark. Enrollment is tracking quite well and is tracking with our guidance of having an initial look at the data later this year. And part of the reason why it's doing well is because we have Pfizer Ignite as a strong partner and we've been able to leverage a lot of their capabilities and being able to drive the enrollment. I think the other things that really do help that I mentioned earlier on the call is that there are no new drugs for 20 years for these RAS mutated patients in first line in CRC. And also importantly, there are no competing trials. Speaker 200:13:19So to answer your question, yes, we're on track with the guidance of initial look later this year. Speaker 400:13:26Okay. Thanks. That's very helpful. And then maybe on the pancreatic trial that you are going to start up. I think nalfurion access are obviously been approved, but at least in our conversations with physicians, it's not 100% clear that it's going to get broadly adopted as a true kind of broad standard of care. Speaker 400:13:49So I guess, why be kind of aggressive on adopting that now kind of for this initial proof of concept for in pancreatic versus maybe using some of the older regimens that are also potentially a bit better tolerated than that regimen? Speaker 200:14:06Yes. Really two answers to that question. I mean the first is that the now ARIFOX really 3 of the 4 chemo agents, we've already combined with onvanceertib in second line and have good data from that. And so we believe that along with our preclinical work in this area. So that's really the first part of the answer to the question. Speaker 200:14:30The second is really that we are showing really good tolerability of ombansertib or tip in combination with these chemo agents and really the only chemo that we haven't combined it with is the oxaliplatin which is part of the null irrefoxed. But really oxaliplatin really does not have any overlapping toxicities with onvanceertib. So we do feel confident that we can come in with this more aggressive chemo and combining and adding value to that because we believe that this is really the type of regimen that is showing the superiority and efficacy in first line. Speaker 400:15:14Okay. Thank you. Operator00:15:19Your next question comes from the line of Andy Scheife of William Blair. Please go ahead. Speaker 400:15:27Great. Thanks for taking our questions. Maybe Speaker 500:15:31kind of extend from Mark's question earlier in the call. Just curious about whether you could comment on the level of excitement and kind of scientific validation with the change of the IST in pancreatic cancer. Obviously, I think it's well validated that onvansertib synergy with irinotecan, which is now included in the regimen versus the gimabraxane regimen before. I'm curious about your view on that. And then in terms of the potential ovarian cancer entry, there's obviously new therapy, new cancer in the form of ADCs. Speaker 500:16:19So you've looked at chemotherapy, you've looked at targeted therapy, combinations, PARP. So just curious about whether you've done or plan do any sort of combinatorial work in the ADC field as well? Thanks. Speaker 200:16:35Thanks Andy for both of those questions. I'd say to answer your first question, really the irinotecan synergy is one of the main reasons we are going with the combination with Naleri Fox in first line. Also the PI that is that we're working with for this new investigator initiated trial has already has experience in our second line pancreatic trial and really was the a huge proponent enthusiastic in going into first line. So that was really he knows our drug, he knows it's well tolerated and he's very excited about going into first line. To answer your other question about ovarian cancer and ADC combination, we are currently pre clinically looking at ADCs in combination with onvansertib, not only ovarian, not specific only on ovarian, but we are really exploring that in several other areas that where ADCs have been approved. Speaker 500:17:41That's helpful. Thank you so much. Speaker 200:17:42Sure. Thanks, Andy. Operator00:18:04There are no more questions. I will now turn the conference back over to Mark Erlander for closing remarks. Speaker 200:18:11Thank you, operator, and this concludes our conference call. Thank you again everybody for joining us this afternoon. Good day. Operator00:18:20Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.Read morePowered by